A New Treatment Strategy that Reduces Growth/Differentiation Factor-15 in Type-2 Diabetes Mellitus: Major Autohemotherapy: A Pilot Study
Yazarlar (2)
Doç. Dr. Hasan Esat YÜCEL
Kırşehir Ahi Evran Üniversitesi, Türkiye
Doç. Dr. Bilal İLANBEY
Kırşehir Ahi Evran Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SCOPUS dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE | ||
| Dergi ISSN | 1078-6791 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | Türkçe | Basım Tarihi | 10-2023 |
| Cilt / Sayı / Sayfa | 29 / 7 / 30–33 | DOI | – |
| Makale Linki | http://alternative-therapies.com/abstract/index.html?id=106153 | ||
| Özet |
| Growth/differentiation factor-15 (GDF-15) is a diagnostic and prognostic marker associated with inflammation, renal damage, and cardiovascular risk in type-2 diabetes mellitus. Researchers have proposed treatment targets that reduce GDF-15 levels. Our aim in this study is to investigate the effect of major autohemotherapy on GDF-15 levels and to evaluate it as a complementary therapy. The research team designed a laboratory study to examine the effect of major hemotherapy on GDF-15 levels in patients with type-2 diabetes mellitus and healthy volunteers. Blood was drawn from the participants in a closed system, infused with ozone gas, and reinfused into the patients. The study was carried out from 15 August-5 October at Kırşehir Training and Research Hospital Traditional and Complementary Medicine Center, Turkey. The study was conducted prospectively, and two groups were formed, consisting of those with type-2 diabetes mellitus (n = 21) and healthy volunteers (n = 14). All participants received 10 sessions of major autohemotherapy at a concentration of 25-35 micrograms/milliliter twice a week. Before and after the application, GDF-15, fasting glucose, glycosylated hemoglobin, and lipid panel levels were studied and compared. Age, GDF-15, fasting glucose, glycosylated hemoglobin, and triglyceride levels were found to be higher in the type-2 diabetes mellitus group compared to the healthy group, and high-density lipoprotein cholesterol levels were found to be lower. After major autohemotherapy, GDF-15 and low-density lipoprotein cholesterol decreased significantly in the type-2 diabetes mellitus group. No change was observed in the healthy group. As a new treatment strategy, major autohemotherapy reduces GDF-15 levels in type-2 diabetes mellitus and contributes to the therapeutic effects of ozone therapy. |
| Anahtar Kelimeler |
